Wellington Shields & Co. LLC decreased its holdings in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) by 30.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 30,091 shares of the biotechnology company’s stock after selling 13,000 shares during the period. Wellington Shields & Co. LLC’s holdings in CASI Pharmaceuticals were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.
Analyst Ratings Changes
Separately, StockNews.com started coverage on CASI Pharmaceuticals in a research report on Tuesday, March 11th. They set a “hold” rating on the stock.
View Our Latest Stock Report on CASI
CASI Pharmaceuticals Price Performance
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Featured Stories
- Five stocks we like better than CASI Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Shanghai Stock Exchange Composite Index?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding CASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report).
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.